Monograph
A03BA03 - Hyoscyamine |
Propably not porphyrinogenic |
PNP |
Rationale
Hoyscyamine is not metabolized by, nor is it reported to have any influence on the activity of any of the cytochrome P450 enzymes. Hyoscyamine shows no pharmacokinetic or pharmacodynamic effects that could point to porphyrinogenicity.
Chemical description
Antimuscarinic tertiary amine alkaloid, levo-isomer to atropine.
Therapeutic characteristics
Hyoscyamine is an anticholinergic used in the symptomatic reliev of gastrointestinal disorders. It is administered orally, often as a depot formulation.
Confounding side effect: constipation.
Metabolism and pharmacokinetics
Hyoscyamine is not metabolized by CYP enzymes.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | DrugBank. hyoscyamine.
|
|
| 2. | McEvoy GK, editor. hyoscyamine. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (30.03.2012).
|
|
| 3. | Sweetman SC, editor. Martindale: The complete drug reference. Hyoscyamine. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 4. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Egazil.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Norway© NAPOS 2024